Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Chief Operating Officer | December 29, 2021 | December 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date December 29, 2021 · Filed December 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 158,942 |
Reported balance
After 2021-12-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-12-29 · Tax withholding · Disposed 2,812 · Balance 158,942 F1: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021. F2: Includes (a) 36,756 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 21,870 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (c) 31,453 restricted stock units with performance based vesting conditions, (d) 18,378 remaining restricted stock units that will vest on December 29, 2022 and 2023, (e) 5,029 remaining restricted stock units that will vest on November 1, 2022, and (f) 45,456 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). |
| Common StockSEC Table I · non-derivative | Direct | 155,595 |
Reported balance
After 2021-12-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-12-29 · Tax withholding · Disposed 3,347 · Balance 155,595 F3: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021. F4: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021.
F2: Includes (a) 36,756 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 21,870 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (c) 31,453 restricted stock units with performance based vesting conditions, (d) 18,378 remaining restricted stock units that will vest on December 29, 2022 and 2023, (e) 5,029 remaining restricted stock units that will vest on November 1, 2022, and (f) 45,456 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan).
F3: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021.
F4: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2021 Filed Dec 30, 2021 21:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 3,347 | $7.27 | $24,332.69 |
DisclosureSEC source: 0000921895-21-002906 · form412799001ols_12302021.xml · nonDerivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,595 F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 21:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 2,812 | $7.27 | $20,443.24 |
DisclosureSEC source: 0000921895-21-002906 · form412799001ols_12302021.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,942 F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021. F2 · balance_after: Includes (a) 36,756 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 21,870 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (c) 31,453 restricted stock units with performance based vesting conditions, (d) 18,378 remaining restricted stock units that will vest on December 29, 2022 and 2023, (e) 5,029 remaining restricted stock units that will vest on November 1, 2022, and (f) 45,456 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 1,539 | $7.37 | $11,342.43 |
DisclosureSEC source: 0000921895-21-002516 · form412799001_11032021.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,754 F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on November 1, 2021. F2 · balance_after: Includes (a) 36,756 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 32,805 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 31,453 restricted stock units with performance based vesting conditions, (d) 27,567 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (e) 5,029 remaining restricted stock units that will vest on November 1, 2022, and (f) 28,144 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 6,480 | $7.64 | $49,507.20 |
DisclosureSEC source: 0000921895-21-001648 · form412799ols_06152021.xml · nonDerivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,293 F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on June 11, 2021. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 18,378 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-001648 · form412799ols_06152021.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,773 F1 · shares: On June 11, 2020, the Reporting Person was granted an award of 36,756 restricted stock units with performance based vesting conditions, which vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the Reporting Person earned 150% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the acquisition of 18,378 additional performance restricted stock units earned above the target grant. F2 · balance_after: Includes (a) 36,756 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 32,805 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 31,453 restricted stock units with performance based vesting conditions, (d) 27,567 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (e) 10,057 remaining restricted stock units that will vest on November 1, 2021 and 2022, and (f) 31,135 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:23 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 31,453 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000616 · form412799ols_03032021.xml · nonDerivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,395 F3 · shares: Represents an award of 31,453 restricted stock units with performance based vesting conditions. These restricted stock units will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from March 1, 2021 to the earlier of (i) December 31, 2023, and (ii) the date of a change of control (the "Measurement Period"), measured relative to the Russell 2000 index and based on the 20-day trading average beginning on the first day of the Measurement Period and ending on the last day of the Measurement Period, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:23 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 32,805 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000616 · form412799ols_03032021.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,942 F1 · shares: Represents an award of 32,805 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 27,567 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 36,756 restricted stock units with performance based vesting conditions tied to relative total shareholder return that will vest on June 11, 2021, 2022 and 2023, (d) 10,057 remaining restricted stock units that will vest on November 1, 2021 and 2022, and (e) 12,757 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:40 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 3,299 | $4.29 | $14,152.71 |
DisclosureSEC source: 0000921895-21-000030 · form412799ols_01052021.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,137 F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person which vested in part on December 31, 2020. F2 · balance_after: Includes (a) 27,567 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023; (b) 36,756 restricted stock units with performance based vesting conditions tied to relative total shareholder return that will vest on June 11, 2021, 2022 and 2023; (c) 10,057 remaining restricted stock units that will vest on November 1, 2021 and 2022; and (d) 12,757 shares of common stock beneficially owned by the Reporting Person (which includes 3,644 shares acquired under the Issuer's Employee Stock Purchase Plan). Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 21:02 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 1,806 | $3.46 | $6,248.76 |
DisclosureSEC source: 0001209191-20-056573 · doc4.xml · nonDerivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,792 F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on November 1, 2020. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 21:02 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Disposition to issuerCommon Stock | 1,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056573 · doc4.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,598 F1 · shares: On November 1, 2019, the Reporting Person was granted an award of 16,949 restricted stock units with performance based vesting conditions based on the achievement of a relative total shareholder return of the Issuer's common stock from November 1, 2019 to the earlier of (i) November 1, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the reporting person earned 89% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the reduction of 1,863 performance restricted stock units from the target grant amount. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 36,756 restricted stock units that will vest on December 31, 2020, 2021, 2022 and 2023; and (c) 36,756 restricted stock units with performance based vesting conditions tied to relative total shareholder return. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:53 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantStock option (right to buy) · Derivative | 79,235 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001209191-20-036763 · doc4.xml · derivative · entry 3 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,235 Underlying: Common Stock · 79,235 shares Expires 2027-06-11 F5 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:53 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 36,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036763 · doc4.xml · nonDerivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,461 F3 · shares: Represents an award of 36,756 restricted stock units with performance based vesting conditions. These restricted stock units will vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:53 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 36,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036763 · doc4.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,705 F1 · shares: Represents an award of 36,756 restricted stock units that will vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. F2 · balance_after: Includes (a) the award described in footnote (1) above, and (b) 16,949 restricted stock units with performance based vesting conditions tied to relative total shareholder return. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 21:07 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantStock option (right to buy) · Derivative | 37,037 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-19-055465 · doc4.xml · derivative · entry 2 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,037 Underlying: Common Stock, par value $0.01 per share · 37,037 shares Expires 2029-11-01 F3 · derivative.exercise_date: The options vest in four equal installments on November 1, 2020, 2021, 2022 and 2023. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 21:07 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055465 · doc4.xml · nonDerivative · entry 1 Olson Kenneth Fletcher · CIK 0001793360 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,949 F1 · shares: Represents a deferred stock award of 16,949 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on November 1, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from November 1, 2019 to the earlier of (i) November 1, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date, or with respect to a change of control, the per share purchase price in the change of control). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F2 · balance_after: Includes the award described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.